$NVCR NovoCure Ltd Insider Trading Week 10/2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NovoCure Ltd.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NovoCure Ltd in week 10/2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 10 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 131.09 | 3,524 | 461,961 | 101,272 | 104.8 K to 101.3 K (-3.36 %) |
| Mar 10 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 130.81 | 2,627 | 343,627 | 104,796 | 107.4 K to 104.8 K (-2.45 %) |
| Mar 10 2021 | NVCR | NovoCure Ltd | Cordova Ashley | Chief Financial Off ... | Sell | S | 130.81 | 765 | 100,067 | 35,893 | 36.7 K to 35.9 K (-2.09 %) |
| Mar 10 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 130.81 | 2,404 | 314,458 | 67,714 | 70.1 K to 67.7 K (-3.43 %) |
| Mar 10 2021 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development O ... | Sell | S | 130.81 | 765 | 100,067 | 90,045 | 90.8 K to 90 K (-0.84 %) |
| Mar 10 2021 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 130.81 | 3,004 | 392,941 | 153,684 | 156.7 K to 153.7 K (-1.92 %) |
| Mar 09 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Option Exercise | M | 7.15 | 13,987 | 100,007 | 0 | |
| Mar 09 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Sell | S | 131.53 | 4,550 | 598,462 | 107,423 | 112 K to 107.4 K (-4.06 %) |
| Mar 09 2021 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Of ... | Buy | M | 7.15 | 13,987 | 100,007 | 111,973 | 98 K to 112 K (+14.27 %) |
| Mar 09 2021 | NVCR | NovoCure Ltd | Benaim Ely | Chief Medical Offic ... | Sell | S | 131.53 | 2,918 | 383,805 | 33,259 | 36.2 K to 33.3 K (-8.07 %) |
| Mar 08 2021 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Off ... | Sell | S | 137.55 | 3,854 | 530,133 | 156,688 | 160.5 K to 156.7 K (-2.40 %) |
| Mar 08 2021 | NVCR | NovoCure Ltd | Longsworth Todd Christopher | General Counsel | Sell | S | 137.55 | 3,084 | 424,217 | 70,118 | 73.2 K to 70.1 K (-4.21 %) |
| Mar 08 2021 | NVCR | NovoCure Ltd | Leonard Frank X | Chief Development O ... | Sell | S | 137.55 | 567 | 77,993 | 90,810 | 91.4 K to 90.8 K (-0.62 %) |
| Mar 08 2021 | NVCR | NovoCure Ltd | Cordova Ashley | Chief Financial Off ... | Gift | G | 0.00 | 910 | 0 | 36,658 | 37.6 K to 36.7 K (-2.42 %) |
| Mar 08 2021 | NVCR | NovoCure Ltd | Cordova Ashley | Chief Financial Off ... | Sell | S | 137.55 | 567 | 77,993 | 37,568 | 38.1 K to 37.6 K (-1.49 %) |